A trial in which rosiglitazone and glipizide were compared supports earlier findings that rosiglitazone does not have an adverse effect on the progression of coronary atherosclerosis ...

Following recent concern that the hypoglycemic agent rosiglitazone might increase the already elevated risk of myocardial infarction in patients with type 2 diabetes, Home et al. conducted an ...

Objective: Published reports suggest that pioglitazone and rosiglitazone have different effects on lipids in patients with type 2 diabetes. However, these previous studies were either ...

A recent study from Yale School of Public Health and other institutions has found that the diabetes drug rosiglitazone is ...

Data Synthesis: Studies of glyburide and glipizide have found little or no transfer of these drugs across the placenta, whereas metformin and rosiglitazone cross readily. Animal studies have found ...